Fri, Oct 18, 2024
The medication is widely prescribed for the treatment of major depressive disorder and for the prevention of seasonal affective disorder.
More >
Thu, Sep 12, 2024
There was a sharp decline in the shares of Granules India today. The objections issued in Form 483 are serious. Why Rolled Granules?
Tue, Aug 20, 2024
Granules India announced that its subsidiary, Granules Pharmaceuticals Inc, has received approval from the US FDA for a generic version of Glycopyrrolate Oral Solution, 1 mg/5 mL. This anticholinergic medication is indicated for pediatric patients aged 3 to 16 years with neurological conditions associated with drooling.
Wed, May 15, 2024
The company said its board has recommended a final dividend of Rs 1.5 per share of face value of Re 1 each for 2023-24.
Tue, Apr 30, 2024
The company's product is therapeutically equivalent to Hikma International Pharmaceuticals LLC's Mitigare Capsules (0.6 mg), it added.
Tue, Jan 23, 2024
"We had a steady performance this quarter, which is reflected in our improved EBITDA and PAT margins as compared to the previous quarter," Granules India Chairman & Managing Director Krishna Prasad Chigurupati said.
Wed, Sep 13, 2023
Granules India's shares climbed over 5 per cent, touching the intra-day high of Rs 323.7 apiece, and IOL Chemicals's shares zoomed over 9 per cent, touching the day's high of Rs 497.45 apiece on the BSE.
Thu, Aug 10, 2023
Net profit declined by 62 per cent year-on-year to Rs 47 crore as against Rs 127 crore in Q1FY23. Gross margins improved marginally by 100 bps from 50 per cent to 51 per cent.
Thu, May 25, 2023
The appropriate containment and remediation actions are being taken in a controlled manner to address the incident, it added.
Tue, May 16, 2023
Granules India Q4 results, dividend news: Granules India — a Hyderabad-based pharma company that makes Paracetamol and Ibuprofen — reported a net profit of Rs 119.6 crore for the quarter ended March 2023, missing analysts' estimates. Granules India's board recommended a dividend of 150 per cent.
Mon, May 15, 2023
Granules India Q4 results preview: Granules India, which manufactures painkiller drug Paracetamol and anti-inflammatory drug Ibuprofen, will report its Q4 results on May 16. Will Granules India also announce a dividend?
Wed, Apr 05, 2023
Stocks to buy today: In conversation with Zee Business, market experts Rakesh Bansal, Kunal Saraogi, Sumeet Bagadia, Himanshu Gupta, and Ambareesh Baliga share their top recommendations for the April 5 session.
Wed, Mar 29, 2023
Stocks to buy today: In conversation with Zee Business Managing Editor Anil Singhvi, market experts Rakesh Bansal, Kunal Saraogi, and Ambareesh Baliga share their top recommendations for the March 29 session.
Mon, Aug 22, 2022
Granules India shares buyback record date: Granules India share buyback price has been fixed at Rs 400 apiece.
Mon, May 23, 2022
The domestic stock market made a sharp recovery on Friday as headline indices surged nearly 3 per cent each on Friday. Broader Nifty50 settled 16,200, while the Sensex gained more than 1500 points to end near 54,300.
Wed, Feb 09, 2022
Besides, for Bajaj Electricals, the brokerage has given an 'add' call at Rs 1,280, against its current price of Rs 1,175.
Sun, Sep 12, 2021
As per the latest Enforcement Report by US Food and Drug Administration (USFDA), the US-based unit of Granules India is recalling over 1.14 crore Naproxen Sodium tablets, a non-steroidal anti-inflammatory drug used to treat pain, menstrual cramps, inflammatory diseases such as rheumatoid arthritis, gout and fever
Fri, Jul 02, 2021
In Zee Business special edition of AajKe2000 show, Managing Editor Anil Singhvi recommends to Buy Granules India shares as the National Pharmaceutical Pricing Authority (NPPA) allowed a 50 per cent price hike on Ibuprofen drug mentioning it a one-time hike as an exceptional measure.
In a major development, the National Pharmaceutical Pricing Authority (NPPA) has allowed to increase the prices of Carbamazepine, Ranitidine and Ibuprofen drugs by 50 per cent, stating that it’s a one-time hike as an exceptional measure.
Wed, Mar 24, 2021
Anil Singhvi said that Granules India is a part of Futures and Options markets now. The Market Guru said there are 2 -3 reasons that could be a big trigger for the stock. Paracetamol demand has been moving up as Covid issue is increasing over the past few days and there are fever / flu concerns among people.
Wed, Mar 17, 2021
Granules India is witnessing a robust outlook across segments and the finished dosages (FD) segment is expected to be a key growth driver. Granules India is looking to increase contribution of the high-margin FD segment to 60% over the next the 2-3 years from 52% (FY2020) backed by a strong product pipeline and growth in existing business. Sharekhan reiterates Buy recommendation on Granules India with an unchanged price target of Rs 475.
Fri, Feb 26, 2021
In Thursday's episode of Special Mid-Cap Stocks, market expert Hemang Jani recommended three more mid-cap stocks with long term, positional medium term and short-term views. These stocks have the potential to get big gains for the investors, he told Zee Business Managing Editor Anil Singhvi. Know what is working for Canfin Homes, Granules India and AU Small Finance Bank stocks here.
Mon, Feb 01, 2021
Granules India Limited (Granules) reported a mixed set of results for Q3 FY21 with the operating performance missing expectations, while higher other income resulted in PAT slightly ahead of estimates. Revenues at Rs 845 cr grew 20% y-o-y backed by strong double digit growth across all the segments of API (Active Pharmaceutical ingredients) – up 20%, PFI (Pharmaceutical formulations intermediates) – up 48% YoY and FD’s (Finished Dosages) up 11.2% yoy.
By accepting cookies, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
